Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.23 USD
Change Today -0.0049 / -2.09%
Volume 2.1M
HEB On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Key Developments

Hemispherx Biopharma Announces Earnings Results for the First Quarter Ended March 2015; Receives European Commission Approval for its Orphan Medicinal Product Application for an Ebola Treatment

Hemispherx Biopharma announced earnings results for the first quarter ended March 2015. For the quarter, net loss, including non-cash effects was approximately $3.4 million or $0.02 per share as compared to a net loss of $3.8 or $0.02 per share for the same three month period in 2014. The company received European Commission approval for its Orphan Medicinal Product Application for an ebola treatment.

Hemispherx Biopharma, Inc. Announces Earnings Results for the Year Ended December 31, 2014

Hemispherx Biopharma, Inc. announced earnings results for the year ended December 31, 2014. For the year, the company reported total revenues were $197,000 compared to $150,000 for the year ended December 31, 2013. Operating loss was $19.1 million compared to operating loss of $17.17 million for the year ended December 31, 2013. Interest and other income was $665,000 compared to $791,000 for the year ended December 31, 2013.

Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus

Hemispherx Biopharma, Inc. will present integrated findings of new studies of Ampligen (rintatolimod), an experimental therapeutic, performed in various models of Ebola virus infection. The findings will be presented during the 7th International Symposium on Filoviruses - Ebola: West Africa and Recent Developments in Washington, DC, March 25-28, 2015. The conference brings together international experts to deal with various aspects of controlling the ongoing Ebola outbreak in West Africa. Hemispherx's commitment regarding research related to pandemic (influenza), and potential pandemic viruses such as SARS, MERS-COV, and Ebola, lies in its belief: these viruses all share a common mechanism of inducing high lethality based on inactivation of innate immunity. Ampligen, an experimental, broad-spectrum antiviral, restores innate immunity in a number of model systems of various pandemic viruses, the scarcity of available experimental therapeutics to test is generally great at the outset of any potential new pandemic which places a high priority on experimental products with a well-developed portfolio of prior animal studies and a known clinical safety profile in other, non-pandemic, disease settings. Double-stranded RNA (dsRNA) is a common component of viral replication and initiates signaling pathways that normally activate innate immune responses, including interferon (IFN) antiviral cascades. Ebola virus disease induces a relative dsRNA deficiency. The IFN induced antiviral pathways include expression of two enzymes, 2'-5' adenylate synthetase and protein kinase R, which require dsRNA as a co-factor for activation. Rintatolimod (PolyI:PolyC12U), Ampligen, an experimental therapeutic, was designed to induce IFN, but with a reduced incidence of adverse events (AEs) compared to polyI:polyC, and has demonstrated broad antiviral activity against both DNA and RNA viruses. The hypothesized mechanism of action against EBOV is that VP35 binding of viral dsRNA creates a relative dsRNA deficiency and blocks IFN induction which Ampligen, a synthetic dsRNA, reverses. Recent results encouraged Hemispherx to move forward its experimental therapeutic Ampligen in the fight against this dread disease presently plaguing West Africa and to continue to work with various international organizations committed to the effort to mitigate the ongoing morbidity and mortality of Ebola. Recently, one of the two experimental therapeutics in active evaluation in West Africa was withdrawn from clinical studies leaving the experimental product, favipiravir, as a principal antiviral agent for active clinical trials. Ampligen also exhibits broad-spectrum antiviral activity against other viruses that are highly pathogenic to humans, including the SARS virus (Day, et al. Virology 2009;395:210-222) and Western Equine Encephalitis Virus (WEEV), where Ampligen demonstrated a greater than 2 fold survival benefit (mice) compared to favipiravir, a potential Ebola treatment (Julander, et al. Antiviral Res 2009;82(3):169-171).

Hemispherx Biopharma, Inc. Announces Earnings Results for the Year Ended December 31, 2014

Hemispherx Biopharma, Inc. announced earnings results for the year ended December 31, 2014. The net loss (including non-cash effects) was approximately $17,450,000 or $0.09 per share as compared to a net loss of $16,225,000 or $0.10 per share for the same twelve month period in 2013.

Hemispherx Biopharma, Inc. Presents at National Investment Banking Association 134th Conference, Mar-23-2015

Hemispherx Biopharma, Inc. Presents at National Investment Banking Association 134th Conference, Mar-23-2015 . Venue: The Roosevelt Hotel, 45 E 45th St, New York, NY 10017, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.23 USD -0.0049

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $301.35 USD +0.13
AstraZeneca PLC 4,474 GBp +48.50
Baxter International Inc $67.37 USD -0.17
Medigene AG €8.47 EUR -0.035
Sarepta Therapeutics Inc $26.22 USD +1.96
View Industry Companies
 

Industry Analysis

HEB

Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 313.0x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 232.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.